Biotechnology Switzerland-based clinical-stage immune-oncology company Anaveon has agreed a 110 million Swiss francs ($120 million) Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. 16 December 2021